MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

Inclusion Criteria: * Meets recipient and/or donor CMV Immunoglobulin G (IgG) serostatus. * Anticipates receiving a primary or secondary allograft kidney at the time of screening and have received a primary or secondary allograft kidney at the time of allocation. * Is within 0 (i.e., day of transplantation) to 7 days (inclusive) post-kidney transplant at the time of allocation. * Is a Japanese male or female from 18 years to any years of age inclusive, at the time of signing the informed consent. * Female is not pregnant or breastfeeding, and is not a woman of childbearing potential (WOCBP); but if a WOCBP, she is using an acceptable contraceptive method, or is abstinent from heterosexual intercourse, and must have a negative highly sensitive pregnancy test within 72 hours before the first dose of study intervention. Exclusion Criteria: * Has received a previous solid organ transplant or hematopoietic stem cell transplant (HSCT). * Is a multi-organ transplant recipient (e.g., kidney-pancreas). * Has a history of CMV disease or suspected CMV disease within 6 months prior to allocation. * Has positive results on CMV assay and/or CMV antigen test at any time between the completion of the transplant surgery and time of allocation. * Has suspected or known hypersensitivity to active or inactive ingredients of LET formulations. * Is on dialysis (for the purposes of this protocol dialysis includes hemofiltration) or plasmapheresis at the time of allocation. * Has Child-Pugh Class…